U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Walter's Pharmacy, Inc. - 506596 - 05/09/2018
  1. Warning Letters


Walter's Pharmacy, Inc. MARCS-CMS 506596 —

Walter's Pharmacy, Inc.

United States

Issuing Office:

United States



Black HHS-Blue FDA Logo



Division of Pharmaceutical Quality Operations I
10 Waterview Blvd, 3rd FL
Parsippany, NJ 07054
Telephone: (973) 331-4900
FAX: (973) 331-4969 

Wednesday, May 9, 2018

Mr. Howard Anthony, Owner
Walter’s Pharmacy, Inc.
401 N 17th St
Allentown, PA 18104-5034

Dear Mr. Anthony:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (17-PHI-03; CMS # 506596) issued on January 11, 2017. We acknowledge that your firm no longer produces sterile drug products. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to assure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. If you decide to resume production of drug products intended to be sterile, FDA strongly recommends that you undertake a comprehensive assessment of your operations, including facility design, and that you notify FDA prior to resuming sterile production. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Diana Amador Toro
Division Director/OPQ Division 1
New Jersey District Office 

Back to Top